Consensus Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E. Other stock markets 01:29:50 16/05/2024 am IST			5-day change	1st Jan Change
4 ^CAD	-0.25%		+1.01%	-25.51%

14/05	Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	MT
08/05	Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Eupraxia Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

51ce5ae82ca5ab722ab.UmpZ5jxT0eP_c05j6hvwiO27IBXxGrlWRSNJruEHESk.JD8D1XoapJeHOT9agi61797df3K5cdw-PEYq_NRDJ1ElRwaSdgSVtI4Jeg~a57ac006f990271900e4f86c8dcd3dbe

Analyst Recommendations on Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Rated Outperform, $7 Target Price at Raymond James

09/22/09

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4 CAD

Average target price

14.45 CAD

Spread / Average Target

+261.25%

High Price Target

16.5 CAD

Spread / Highest target

+312.50%

Low Price Target

12.4 CAD

Spread / Lowest Target

+210.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Eupraxia Pharmaceuticals Inc.

Raymond James

Quarterly revenue - Rate of surprise

Company calendar